Bulgarian patients blame state policy for poor access to medicines
This article was originally published in RAJ Devices
Executive Summary
Within the last 12 months, almost 18% of Bulgarian patents stopped taking prescribed medicines, citing financial reasons. A further 70% believe that drug expenditure incurred during treatment is a significant burden for their personal budgets. According to a recent poll carried out by consultancy Gallup International, Bulgarian patients are deeply unhappy with the healthcare policy carried out by the government and believe that state expenditure in this area should be increased.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.